Stock 600513 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Equities

600513

CNE000001DP6

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/06/2024 BST 		5-day change 1st Jan Change
8.21 CNY +3.01% Intraday chart for Jiangsu Lianhuan Pharmaceutical Co., Ltd. 0.00% -26.30%
08:47am Lianhuan Pharmaceutical's Moxifloxacin Hydrochloride Tablets Get Drug Registration Certificate MT
06-20 China Grants Active Pharmaceutical Ingredient Marketing Approval for Lianhuan Pharma's Cardiac Treatment MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,698 2,244 2,969 2,782 2,696 3,180
Enterprise Value (EV) 1 1,506 2,284 3,112 3,010 3,055 3,604
P/E ratio 22.9 x 27.8 x 28.6 x 23.6 x 19.2 x 23.7 x
Yield 1.31% 1.08% 1.05% 1.29% 1.6% 1.35%
Capitalization / Revenue 1.67 x 1.74 x 2.14 x 1.69 x 1.38 x 1.46 x
EV / Revenue 1.48 x 1.77 x 2.25 x 1.83 x 1.56 x 1.66 x
EV / EBITDA 14.2 x 18.3 x 17.7 x 15.1 x 12.2 x 15.3 x
EV / FCF -92.6 x -15.5 x -24.5 x -39.5 x -23.1 x -55.1 x
FCF Yield -1.08% -6.44% -4.08% -2.53% -4.34% -1.81%
Price to Book 1.83 x 2.27 x 2.77 x 2.4 x 2.13 x 2.35 x
Nbr of stocks (in thousands) 285,456 288,105 287,990 287,990 287,146 285,456
Reference price 2 5.950 7.790 10.31 9.660 9.390 11.14
Announcement Date 27/03/19 24/04/20 30/03/21 27/04/22 02/03/23 05/03/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,019 1,290 1,386 1,646 1,955 2,174
EBITDA 1 105.8 125.1 175.7 199.3 251.2 235.6
EBIT 1 83.37 104.8 153.9 171.5 210.7 180
Operating Margin 8.18% 8.12% 11.11% 10.42% 10.78% 8.28%
Earnings before Tax (EBT) 1 87.82 101.5 142 159.6 189.1 175
Net income 1 73.56 79.73 103 118.8 141.4 135
Net margin 7.22% 6.18% 7.43% 7.22% 7.23% 6.21%
EPS 2 0.2600 0.2800 0.3600 0.4100 0.4900 0.4700
Free Cash Flow 1 -16.26 -147.1 -127 -76.16 -132.5 -65.41
FCF margin -1.6% -11.4% -9.16% -4.63% -6.77% -3.01%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.0780 0.0840 0.1080 0.1250 0.1500 0.1500
Announcement Date 27/03/19 24/04/20 30/03/21 27/04/22 02/03/23 05/03/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 39.4 143 228 359 424
Net Cash position 1 192 - - - - -
Leverage (Debt/EBITDA) - 0.3154 x 0.8147 x 1.144 x 1.429 x 1.802 x
Free Cash Flow 1 -16.3 -147 -127 -76.2 -132 -65.4
ROE (net income / shareholders' equity) 8.13% 8.2% 10.6% 11.4% 12.4% 10.3%
ROA (Net income/ Total Assets) 4.03% 3.96% 4.89% 4.87% 5.19% 4.04%
Assets 1 1,824 2,014 2,108 2,441 2,721 3,343
Book Value Per Share 2 3.260 3.430 3.720 4.020 4.410 4.740
Cash Flow per Share 2 1.040 1.000 0.8400 1.150 1.150 0.9900
Capex 1 128 169 174 172 221 201
Capex / Sales 12.59% 13.07% 12.57% 10.46% 11.29% 9.23%
Announcement Date 27/03/19 24/04/20 30/03/21 27/04/22 02/03/23 05/03/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD. Stock Jiangsu Lianhuan Pharmaceutical Co., Ltd.
-26.30% 323M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.29% 811B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.96% 640B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.46% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.41% 333B
ABBVIE INC. Stock AbbVie Inc.
+9.82% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.34% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+2.62% 225B
NOVARTIS AG Stock Novartis AG
+12.91% 218B
AMGEN INC. Stock Amgen Inc.
+9.13% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600513 Stock
  4. Financials Jiangsu Lianhuan Pharmaceutical Co., Ltd.